Skip to main content
2025 AABB Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Event Icons
Assessor Sessions
Assessor Sessions
Committee Meetings
Committee Meetings
Foundation Events
Foundation Events
Networking Events
Networking Events
Oral Abstracts
Oral Abstracts
CABP Eligible
CABP Eligible
Video Recording

AM25-MN-40-L - COVID-19 Convalescent Plasma in the Immunocompromised Patient

Monday, October 27, 2025
3:45 PM - 4:45 PM  PT
Room: SDCC 20A
CE: 1 CME (AMA Physician Credit) / 1 CE (Non-Physician Credit)
The session will provide an update on the use of COVID-19 Convalescent Plasma (CCP) as a critical therapy in immunocompromised patients. The session will highlight the rationale and evidence for this immunocompromised patient use case, antibody qualifications for the use of convalescent plasma, the FDA’s actions supporting CCP from the early weeks of the public health emergency to the new regulatory pathway for licensure of CCP, and the currently available sources of convalescent plasma.

Learning Objectives:

  • Describe the ongoing use of high titer Convalescent Plasma and the benefits to immunocompromised patients. 
  • Describe the current and future use of convalescent plasma
  • Describe FDA’s recommendations to blood establishments for the submission of a Biologics License Application for the manufacture of COVID-19 convalescent plasma for transfusion intended to treat inpatients and outpatients with immunosuppressive disease or receiving immunosuppressive treatment.
  • Describe a blood center’s experience in submitting a Biologics License Application for CCP to the FDA